Dosing Regimens Before and During Long-Term Treatment with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A: An Updated Analysis of the ASPIRE Study

被引：0
|
作者：
Nolan, B. [1 ]
Young, G. [2 ]
Mahlangu, J. N. [3 ,4 ]
Liesner, R. [5 ]
Pasi, K. J. [6 ]
Yuan, H. [7 ]
Winding, B. [8 ]
Ramirez-Santiago, A. [7 ]
Dumont, J. [7 ]
Lethagen, S. [8 ,9 ]
Glazebrook, D. V. [7 ]
机构：
[1] Our Ladys Childrens Hosp, Dublin, Ireland
[2] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[3] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
[4] Univ Witwatersrand, Natl Hlth Lab Serv, Johannesburg, South Africa
[5] Great Ormond St Hosp Sick Children, London, England
[6] Barts & London Comprehens Care Ctr, London, England
[7] Biogen, Cambridge, MA USA
[8] Sobi, Stockholm, Sweden
[9] Univ Copenhagen, Copenhagen, Denmark
来源：
HAEMOPHILIA | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P023
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [31] Dosing Long-Lasting Recombinant Factor VIII Fc Fusion Protein: Experience In The A-LONG Study
    Shapiro, Amy
    Ragni, Margaret V.
    Kulkarni, Roshni
    Kulke, Sarah
    Potts, James
    Neelakantan, Srividya
    Nestorov, Ivan
    Dumont, Jennifer A.
    Jiang, Haiyan
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2013, 122 (21)
  • [32] Safety and efficacy of recombinant factor VIII FC fusion protein (RFVIIIFC) for the prevention and treatment of bleeding in previously-treated adult and adolescent subjects with hemophilia A: interim analysis of the aspire study
    Jackson, S.
    Perry, D.
    Quon, D.
    Chowdary, P.
    Shapiro, A.
    Pabinger, I
    Santagostino, E.
    Li, X.
    Glazebrook, D., V
    Allen, G. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 346 - 347
  • [33] POPULATION PHARMACOKINETIC MODEL FOR RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) VALIDATED AND OPTIMIZED FOR USE IN CHILDREN
    Bukkems, L. H.
    Heijdra, J. M.
    Mathias, M.
    Collins, P. W.
    Hay, C. R. M.
    Leebeek, F. W. G.
    Meijer, K.
    Fijnvandraat, K.
    Chowdary, P.
    Cnossen, M. H.
    Mathot, R. A. A.
    HAEMATOLOGICA, 2019, 104 : 14 - 14
  • [34] Clinical development of rFVIIIFc, a novel, long-lasting recombinant Fc fusion replacement factor, in patients with severe haemophilia A
    Powell, J.
    Josephson, N.
    Perry, D.
    Nugent, K.
    Gor, D.
    Pestana, H.
    Francpoole, E.
    Li, L.
    Greblikas, F.
    Allen, G.
    Dabora, S.
    Krassova, S.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2012, 18 : 39 - 39
  • [35] Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a
    Konkle, Barbara
    Pasi, K. John
    Perry, David J.
    Mahlangu, Johnny
    Rangarajan, Savita
    Brown, Simon A.
    Hanabusa, Hideji
    Pabinger, Ingrid
    Cristiano, Lynda M.
    Tsao, Elisa
    Winding, Bent
    Glazebrook, Desilu
    Lethagen, Stefan
    Jackson, Shannon
    BLOOD, 2016, 128 (22)
  • [36] Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
    Bullement, Ash
    McMordie, Samuel Thomas
    Hatswell, Anthony James
    Li, Nanxin
    Wilson, Koo
    PHARMACOECONOMICS-OPEN, 2020, 4 (01) : 133 - 142
  • [37] Recombinant factor VIII Fc fusion protein as episodic treatment for bleeding: Analysis from the A-LONG Study
    Shapiro, Amy
    Chowdary, Pratima
    Quon, Doris
    Lin, Judith
    Neelakantan, Srividya
    Jiang, Haiyan
    Dodd, Nigel
    Brennan, Aoife
    Allen, Geoff
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 16 - 16
  • [38] Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
    Ash Bullement
    Samuel Thomas McMordie
    Anthony James Hatswell
    Nanxin Li
    Koo Wilson
    PharmacoEconomics - Open, 2020, 4 : 133 - 142
  • [39] Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein
    Oldenburg, J.
    Kulkarni, R.
    Srivastava, A.
    Mahlangu, J. N.
    Blanchette, V. S.
    Tsao, E.
    Winding, B.
    Dumont, J.
    Jain, N.
    HAEMOPHILIA, 2018, 24 (01) : 77 - 84
  • [40] Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis
    Carcao, M.
    Shapiro, A.
    Staber, J. M.
    Hwang, N.
    Druzgal, C.
    Lieuw, K.
    Belletrutti, M.
    Thornburg, C. D.
    Ahuja, S. P.
    Morales-Arias, J.
    Dumont, J.
    Miyasato, G.
    Tsao, E.
    Jain, N.
    Pipe, S. W.
    HAEMOPHILIA, 2018, 24 (02) : 245 - 252
12345